iPS 세포(유도만능줄기세포) 시장 규모, 점유율, 동향 분석 리포트 : 유래 세포 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Induced Pluripotent Stem Cells Market Growth & Trends:

The global induced pluripotent stem cells market size is expected to reach USD 3.31 billion by 2030, registering to grow at a CAGR of 10.21% from 2024 to 2030 according to a new report by Grand View Research, Inc. The market for induced pluripotent stem cells (iPSC) is expanding quickly. The ability of induced pluripotent stem cells to generate any cell or tissue essential by the body to fight or combat illnesses such as leukemia, spinal cord injury, cardiovascular disease, and diabetes is the primary reason for their utilization.

Other factors driving market expansion include higher research funding, an increase in the number of genomics initiatives, and a surge in the application of genome engineering in personalized drugs. This has accelerated the adoption of iPSC, resulting in the market's profitable revenue growth. For instance, in October 2020, Axxam S.p.A. & FUJIFILM Cellular Dynamics, Inc. announced a strategic partnership to advance the drug discovery process. Through the use of the most cutting-edge drug discovery techniques to enable target evaluation, High-Throughput Screening (HTS), & High-Content Screening, the partnership will give drug development researchers along with scientists access to an integrative platform of hiPSC-based assays.

Investments in healthcare development and research have expanded significantly in recent years, and this trend is projected to have a significant impact on induced pluripotent stem cell demand over the forecast period. The expanding spectrum of human iPSC cell lines' applications in precision medicine and the growing emphasis on stem cell therapeutic applications are predicted to be important factors driving induced pluripotent stem cell market expansion. For instance, in March 2021, Sana Biotechnology, Inc. received authorization to use FUJIFILM Cellular Dynamics' iPSC platform for the creation of commercially available cell therapies, according to a joint statement from both companies. Cell therapies can improve, fix, or substitute human biology, including cells, tissues, and organs.

The rise in research activity during the COVID-19 pandemic also enhanced iPSC-based research. In addition, scientists' ongoing efforts to discover novel therapies and treatments to manage the SARS CoV-2 infection have increased the need for iPSCs as research tools. Furthermore, induced pluripotent stem cells can create organoids or organ models that are physiologically equivalent, thus they can be utilized to study the pathophysiology of viral infection in humans. Thus, propelling the industry growth.

Furthermore, the government and commercial sectors are expanding funding along with growing industry that focuses on various scientific activities linked to iPSCs, and people are becoming more aware of stem cells through various organizations. However, challenges such as the high cost of cell reprograming, ethical concerns, and lengthy processes are inhibiting the growth of the induced pluripotent stem cell industry to a certain extend Moreover, low efficiency, potential tumor risk, and insufficient programming are other concerns restricting the expansion of the iPSC market.

Induced Pluripotent Stem Cells Market Report Highlights:

• By derived cell type, the fibroblasts segment accounted for the largest share of 30.51% in 2023. The growing preference among healthcare professionals for fibroblast as potential treatments for skin problems are propelling the segment growth.
• By application, the drug developmentsegment accounted for the largest share of 49.03% in 2023. The prevalence of chronic diseases, sedentary lifestyle, and others increase the demand for personalized therapies, and the increasing interest of pharma & biotech companies to develop drugs with the help of iPS cells promotes the industry growth.
• By end-user, the pharmaceutical & biotechnology companies segment accounted for the largest share of 59.83% in 2023. This segment is projected to dominate the market since they make and develop various stem cell products & technology for various diseases employing induced pluripotent stem cells.
• North America held the larger share of 36.11% in 2023. This is mostly due to increased use of innovative systems and technologies in drug research, toxicity testing, and disease modeling, as well as the region's growing acceptance of stem cell therapies are the major reasons for driving the market.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Derived Cell Type Segment
  • 1.2.2. Application Segment
  • 1.2.3. End Use Segment
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Induced Pluripotent Stem Cells Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of chronic diseases
    • 3.2.1.2. Increasing research and development activities in stem cell therapies
    • 3.2.1.3. Growing adoption of personalized medicine
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment
• 3.3. Induced Pluripotent Stem Cells Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Induced Pluripotent Stem Cells Market: Derived Cell Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Induced Pluripotent Stem Cells Market Derived Cell Type Movement Analysis
• 4.3. Global Induced Pluripotent Stem Cells Market Size & Trend Analysis, by Derived Cell Type, 2018 to 2030 (USD Million)
• 4.4. Hepatocytes
  • 4.4.1. Hepatocytes market estimates and forecasts 2018 - 2030 (USD Million)
• 4.5. Fibroblasts
  • 4.5.1. Fibroblasts market estimates and forecasts 2018 - 2030 (USD Million)
• 4.6. Keratinocytes
  • 4.6.1. Keratinocytes market estimates and forecasts 2018 - 2030 (USD Million)
• 4.7. Amniotic Cells
  • 4.7.1. Amniotic cells market estimates and forecasts 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Induced Pluripotent Stem Cells Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Induced Pluripotent Stem Cells Market Application Movement Analysis
• 5.3. Global Induced Pluripotent Stem Cells Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Drug Development
  • 5.4.1. Drug development market estimates and forecasts 2018 - 2030 (USD Million)
• 5.5. Tissue Engineering & Regenerative Medicine
  • 5.5.1. Tissue engineering & regenerative medicine market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.2. Neurology
    • 5.5.2.1. Neurology market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.3. Orthopedics
    • 5.5.3.1. Orthopedics market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.4. Oncology
    • 5.5.4.1. Oncology market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.5. Cardiovascular & Myocardial Infarction
    • 5.5.5.1. Cardiovascular & myocardial infarction market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.6. Diabetes
    • 5.5.6.1. Diabetes market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5.7. Others
    • 5.5.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)
• 5.6. Toxicology Research
  • 5.6.1. Toxicology research market estimates and forecasts 2018 - 2030 (USD Million)
• 5.7. Disease Modeling
  • 5.7.1. Disease modeling market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Induced Pluripotent Stem Cells Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Induced Pluripotent Stem Cells Market End Use Movement Analysis
• 6.3. Global Induced Pluripotent Stem Cells Market Size & Trend Analysis, by End use, 2018 to 2030 (USD Million)
• 6.4. Academic & Research Institutes
  • 6.4.1. Academic & research institutes market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5. Pharmaceutical & Biotechnology Companies
  • 6.5.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Induced Pluripotent Stem Cells Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. Target disease prevalence
    • 7.4.2.5. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Target disease prevalence
    • 7.4.3.5. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Target disease prevalence
    • 7.4.4.5. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Target disease prevalence
    • 7.5.2.5. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Target disease prevalence
    • 7.5.3.5. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. Target disease prevalence
    • 7.5.4.5. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Target disease prevalence
    • 7.5.5.5. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Target disease prevalence
    • 7.5.6.5. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Target disease prevalence
    • 7.5.7.5. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Competitive scenario
    • 7.5.8.3. Regulatory framework
    • 7.5.8.4. Target disease prevalence
    • 7.5.8.5. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key country dynamics
    • 7.5.9.2. Competitive scenario
    • 7.5.9.3. Regulatory framework
    • 7.5.9.4. Target disease prevalence
    • 7.5.9.5. Norway market estimates and forecasts 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Target disease prevalence
    • 7.6.2.5. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Target disease prevalence
    • 7.6.3.5. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. Target disease prevalence
    • 7.6.4.5. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Regulatory framework
    • 7.6.5.4. Target disease prevalence
    • 7.6.5.5. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Regulatory framework
    • 7.6.6.4. Target disease prevalence
    • 7.6.6.5. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Competitive scenario
    • 7.6.7.3. Regulatory framework
    • 7.6.7.4. Target disease prevalence
    • 7.6.7.5. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Target disease prevalence
    • 7.7.2.5. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Target disease prevalence
    • 7.7.3.5. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. Target disease prevalence
    • 7.8.2.5. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. Regulatory framework
    • 7.8.3.4. Target disease prevalence
    • 7.8.3.5. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Competitive scenario
    • 7.8.4.3. Regulatory framework
    • 7.8.4.4. Target disease prevalence
    • 7.8.4.5. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key country dynamics
    • 7.8.5.2. Competitive scenario
    • 7.8.5.3. Regulatory framework
    • 7.8.5.4. Target disease prevalence
    • 7.8.5.5. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2023
• 8.4. Company Profiles/Listing
  • 8.4.1. STEMCELL Technologies Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Cellular Engineering Technologies Inc.
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. REPROCELL Inc.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Takara Bio, Inc.
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Axol Bioscience Ltd.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Fate Therapeutics, Inc.
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. FUJIFILM Cellular Dynamics, Inc.
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Cynata Therapeutics Limited
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Evotec SE
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Astellas Pharma Inc.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives